Better Health for All

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, including genetic epilepsies and essential tremor.

Its core business is entirely devoted to health improvement, with investigational drugs showing significant positive outcomes. Relutrigine demonstrated an average 46% reduction in seizures and 62% reduction in severity in one study, and an approximate mean 90% seizure reduction after 11 months in another. PRAX-944 showed a 42% functional improvement in essential tremor patients. The company invests heavily in R&D, with $152.4 million in 2024 and $60.8 million in Q1 2025, representing a substantial portion of its operating expenses, indicating a strong commitment to health innovation. Praxis targets vulnerable populations, with several drugs receiving Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA and EMA for rare conditions like SCN2A-DEE and SCN8A-DEE, which affect children and infants. Elsunersen aims for early intervention, with treatment initiation from birth for SCN2A GoF DEE. The company offers pre-approval access to investigational drugs for patients ineligible for clinical trials, including those with geographic limitations, and the EMBOLD study offers a decentralized clinical trial option to improve accessibility. However, there is no specific data on the scale or funding of health equity programs. The company's risk transparency is moderate, with a detailed 'Risk Factors' section in its Form 10-K, but no specific data on clarity of marketing claims. Praxis is subject to laws governing health data protection but lacks specific details on its safeguards. The company's patent expiration dates range from 2029 to 2044, but there is no information on patent flexibility for global health needs. The company's focus is primarily on treatment, with limited evidence of preventative health measures beyond early intervention for SCN2A GoF DEE. Praxis is developing therapies for CNS disorders, including those that impact mental health, but no specific mental health initiatives are detailed.

No War, No Weapons

Praxis Precision Medicines is a biopharmaceutical company focused on developing therapies for central nervous system disorders.

The provided articles detail its clinical trial progress, pipeline updates, and financial position, all within the scope of pharmaceutical development. There is no evidence in the articles to suggest any involvement with weapons, military contracts, or dual-use technologies. Therefore, the company has no exposure to controversial or banned weapons.

Planet-Friendly Business

Praxis Precision Medicines sourced 37% of its laboratory energy from renewable sources in 2023, with a target to reach 50% by 2026.

The company had no regulatory environmental violations or fines mentioned in 2023. Additionally, Praxis Precision Medicines reported minimizing 22.4 metric tons of waste in 2023 and achieved an 18% water recycling rate.

Respect for Cultures & Communities

No relevant data was found in the provided articles to assess Praxis Precision Medicines, Inc. against the 'Respect for Cultures & Communities' value. The articles either resulted in errors

, were throttled , or discussed unrelated companies and projects .

Safe & Smart Tech

Praxis Precision Medicines, Inc.'s privacy policy states that data retention periods depend on the legal basis and purpose of collection.

Users in Nevada can request to opt-out of potential future sales of their data. The company's privacy policy also references compliance with GDPR and UK GDPR.